Corvus Pharmaceuticals/$CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
$CRVS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
31
ISIN
US2210151005
Website
CRVS Metrics
BasicAdvanced
$328M
-
-$0.99
0.66
-
Price and volume
Market cap
$328M
Beta
0.66
52-week high
$9.28
52-week low
$2.10
Average daily volume
981K
Financial strength
Current ratio
4.903
Quick ratio
4.789
Long term debt to equity
1.691
Total debt to equity
2.338
Profitability
EBITDA (TTM)
-31.133
Management effectiveness
Return on assets (TTM)
-39.21%
Return on equity (TTM)
-100.13%
Valuation
Price to book
5.87
Price to tangible book (TTM)
5.87
Price to free cash flow (TTM)
-9.932
Free cash flow yield (TTM)
-10.07%
Free cash flow per share (TTM)
-42.79%
Growth
Earnings per share change (TTM)
93.07%
3-year earnings per share growth (CAGR)
3.72%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
Bulls say / Bears say
Corvus Pharmaceuticals' lead candidate, soquelitinib, has demonstrated favorable safety and efficacy in Phase 1 trials for atopic dermatitis, with earlier and deeper responses observed in the latest cohort. (Corvus Pharmaceuticals Press Release)
The company has initiated a Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL), indicating progress towards potential market approval. (Corvus Pharmaceuticals Press Release)
Analysts at Oppenheimer have raised their price target for Corvus Pharmaceuticals to $17.00, reflecting confidence in the company's growth prospects. (ETF Daily News)
Corvus Pharmaceuticals reported a net loss of $12.1 million for Q4 2024, indicating ongoing financial challenges. (Corvus Pharmaceuticals Press Release)
StockNews.com downgraded Corvus Pharmaceuticals to a 'sell' rating, suggesting concerns about the company's future performance. (ETF Daily News)
Despite positive trial results, the company's stock price has experienced volatility, with a recent downgrade potentially impacting investor confidence. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 14 Jul 2025.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
CRVS News
AllArticlesVideos
3 Penny Stocks Wall Street Sees With 243% Upside
24/7 Wall Street·1 month ago
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewsWire·1 month ago
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $328M as of July 18, 2025.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of July 18, 2025.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.